Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT05321316 | — | Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors | Nectin-4 -- imaging probe for PET detection of nectin-4 expression (radiotracer) |
| NCT04858334 | 2 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | PARP inhibition (Olaparib) |
| NCT06752811 | 3 | Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer | Polymeric micellar paclitaxel + gemcitabine chemotherapy |
| NCT07873606 | — | Histotripsy x Pancreatic Cancer | Unknown mechanism |
| NCT07945782 | 1, 2 | A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer | PD-1 (via toripalimab/ iparomlimab) -- immune checkpoint blockade (monoclonal antibody) combined with DNA-damaging chemotherapy (gemcitabine) and radiotherapy (multimodal therapy) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 20 |
| Tianjin Medical University Cancer Institute and Hospital | 18 |
| Ruijin Hospital | 14 |
| Zhejiang University | 12 |
| Minia University | 9 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 1, 2027 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Apr 13, 2027 | NCT07898813 | Daraxonrasib in Resectable PDAC | KRAS -- covalent inhibitor (small molecule) |
| Jan 15, 2027 | NCT07905131 | A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | EZH2 -- methyltransferase inhibitor (epigenetic modulator) |
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Dec 1, 2026 | NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | CDK7 -- kinase inhibitor (small molecule) |
| Dec 1, 2026 | NCT07945782 | A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer | PD-1 (via toripalimab/ iparomlimab) -- immune checkpoint blockade (monoclonal antibody) combined with DNA-damaging chemotherapy (gemcitabine) and radiotherapy (multimodal therapy) |
| Dec 2026 | NCT07444541 | ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer | CLDN18.2 -- monoclonal antibody |
| Dec 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.